National Vaccine Injury Compensation Program: Revisions to the Vaccine Injury Table; Notice of Proposed Rulemaking; Public Comment Period; Delay of Effective Date, 9308-9309 [2021-03069]
Download as PDF
9308
Federal Register / Vol. 86, No. 28 / Friday, February 12, 2021 / Proposed Rules
substantial changes to the amendment.
IPCB also adopted minor administrative
changes such as alphabetizing
compound names and adopting IUPAC
names for some compounds listed at 35
IAC 211.7150.
III. EPA’s Analysis of the Proposed SIP
Revision
In 2014, EPA received a petition
requesting that cis-1,1,1,4,4,4hexafluorobut-2-ene be exempted from
VOC control based on its low reactivity,
using ethane as a benchmark. Based on
the mass maximum incremental
reactivity value for the compound being
less than that of ethane, EPA concluded
that this compound makes negligible
contributions to tropospheric ozone
formation. Additionally, EPA
considered risks not related to
tropospheric ozone associated with
currently allowed uses of the chemical
to be acceptable. As a result, on
November 28, 2018, EPA responded to
the petition by amending 40 CFR
51.100(s) to exclude this chemical
compound from the definition of VOC
for purposes of preparing SIPs to attain
the national ambient air quality
standard for ozone under title I of the
CAA. See 83 FR 61127 (Nov. 28, 2018).
EPA’s action became effective on
January 28, 2019.
By excluding cis-1,1,1,4,4,4hexafluorobut-2-ene from the definition
of VOM at 35 IAC 211.7150, Illinois’
proposed SIP revision is consistent with
EPA’s action amending the definition of
VOC at 40 CFR 51.100(s).
IV. What action is EPA taking?
EPA is proposing to approve the
revision to the Illinois SIP at 35 IAC
211.7150 submitted on October 20,
2020. The proposed approval of the
revision meets the criteria of the CAA
and applicable Federal regulations.
V. Incorporation by Reference
In this rule, EPA is proposing to
include in a final EPA rule regulatory
text that includes incorporation by
reference. In accordance with
requirements of 1 CFR 51.5, EPA is
proposing to incorporate by reference
revisions to 35 IAC 211.7150 ‘‘Volatile
Organic Material (VOM) or Volatile
Organic Compound (VOC)’’, effective
August 18, 2020. EPA has made, and
will continue to make, these documents
generally available through
www.regulations.gov and at the EPA
Region 5 Office (please contact the
person identified in the FOR FURTHER
INFORMATION CONTACT section of this
preamble for more information).
VerDate Sep<11>2014
17:15 Feb 11, 2021
Jkt 253001
VI. Statutory and Executive Order
Reviews
Under the CAA the Administrator is
required to approve a SIP submission
that complies with the provisions of the
CAA and applicable Federal regulations.
42 U.S.C. 7410(k); 40 CFR 52.02(a).
Thus, in reviewing SIP submissions,
EPA’s role is to approve state choices,
provided that they meet the criteria of
the CAA. Accordingly, this action
merely approves state law as meeting
Federal requirements and does not
impose additional requirements beyond
those imposed by state law. For that
reason, this action:
• Is not a significant regulatory action
subject to review by the Office of
Management and Budget under
Executive Orders 12866 (58 FR 51735,
October 4, 1993) and 13563 (76 FR 3821,
January 21, 2011);
• Is not an Executive Order 13771 (82
FR 9339, February 2, 2017) regulatory
action because SIP approvals are
exempted under Executive Order 12866;
• Does not impose an information
collection burden under the provisions
of the Paperwork Reduction Act (44
U.S.C. 3501 et seq.);
• Is certified as not having a
significant economic impact on a
substantial number of small entities
under the Regulatory Flexibility Act (5
U.S.C. 601 et seq.);
• Does not contain any unfunded
mandate or significantly or uniquely
affect small governments, as described
in the Unfunded Mandates Reform Act
of 1995 (Pub. L. 104–4);
• Does not have federalism
implications as specified in Executive
Order 13132 (64 FR 43255, August 10,
1999);
• Is not an economically significant
regulatory action based on health or
safety risks subject to Executive Order
13045 (62 FR 19885, April 23, 1997);
• Is not a significant regulatory action
subject to Executive Order 13211 (66 FR
28355, May 22, 2001);
• Is not subject to requirements of
Section 12(d) of the National
Technology Transfer and Advancement
Act of 1995 (15 U.S.C. 272 note) because
application of those requirements would
be inconsistent with the Clean Air Act;
and
• Does not provide EPA with the
discretionary authority to address, as
appropriate, disproportionate human
health or environmental effects, using
practicable and legally permissible
methods, under Executive Order 12898
(59 FR 7629, February 16, 1994).
In addition, the SIP is not approved
to apply on any Indian reservation land
or in any other area where EPA or an
PO 00000
Frm 00005
Fmt 4702
Sfmt 4702
Indian tribe has demonstrated that a
tribe has jurisdiction. In those areas of
Indian country, the rule does not have
tribal implications and will not impose
substantial direct costs on tribal
governments or preempt tribal law as
specified by Executive Order 13175 (65
FR 67249, November 9, 2000).
List of Subjects in 40 CFR Part 52
Environmental protection, Air
pollution control, Incorporation by
reference, Intergovernmental relations,
Ozone, Reporting and recordkeeping
requirements, Volatile organic
compounds.
Dated: February 4, 2021.
Cheryl Newton,
Acting Regional Administrator, Region 5.
[FR Doc. 2021–02744 Filed 2–11–21; 8:45 am]
BILLING CODE 6560–50–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
42 CFR Part 100
RIN 0906–AB24
National Vaccine Injury Compensation
Program: Revisions to the Vaccine
Injury Table; Notice of Proposed
Rulemaking; Public Comment Period;
Delay of Effective Date
Health Resources and Services
Administration (HRSA), Department of
Health and Human Services (HHS).
ACTION: Notice of proposed rulemaking;
proposed delay of effective date; request
for comments.
AGENCY:
In accordance with the
Presidential directive as expressed in
the memorandum of January 20, 2021,
from the Assistant to the President and
Chief of Staff, entitled ‘‘Regulatory
Freeze Pending Review,’’ this action
proposes, following a brief public
comment period, to further delay until
April 23, 2021, the effective date of the
rule entitled ‘‘National Vaccine Injury
Compensation Program: Revisions to the
Vaccine Injury Table,’’ published in the
Federal Register on January 21, 2021.
That final rule is scheduled to take
effect on February 22, 2021. HHS seeks
comments on this proposed delay,
which would allow it additional
opportunity for review and
consideration of the new rule.
DATES: Written comments and related
material to this proposed rule must be
received to the online docket via https://
www.regulations.gov on or before
February 16, 2021.
ADDRESSES: You may submit written
comments electronically by the
SUMMARY:
E:\FR\FM\12FEP1.SGM
12FEP1
Federal Register / Vol. 86, No. 28 / Friday, February 12, 2021 / Proposed Rules
following method: Federal eRulemaking
Portal: https://www.regulations.gov.
Follow the instructions on the website
for submitting comments.
Instructions. Include the HHS Docket
No. HRSA–2021–0001 in your
comments. All comments received will
be posted without change to https://
www.regulations.gov. Please do not
include any personally identifiable or
confidential business information you
do not want publicly disclosed.
FOR FURTHER INFORMATION CONTACT:
Please visit the National Vaccine Injury
Compensation Program’s website,
https://www.hrsa.gov/vaccine
compensation/, or contact Tamara
Overby, Acting Director, Division of
Injury Compensation Programs,
Healthcare Systems Bureau, HRSA,
Room 08N146B, 5600 Fishers Lane,
Rockville, MD 20857; by email at
vaccinecompensation@hrsa.gov; or by
telephone at (855) 266–2427.
SUPPLEMENTARY INFORMATION: HHS
published a notice of proposed
rulemaking on July 20, 2020 (85 FR
43794), and final rule on January 21,
2021 (86 FR 6249). That final rule
amended the provisions of 42 CFR 100.3
by removing Shoulder Injury Related to
Vaccine Administration, vasovagal
syncope, and Item XVII from the
Vaccine Injury Table. The January 20,
2021, memorandum from the Assistant
to the President and Chief of Staff,
entitled ‘‘Regulatory Freeze Pending
Review,’’ instructed federal agencies to
consider delaying the effective date of
rules published in the Federal Register,
but which have not yet taken effect, for
a period of 60 days so that the new
Administration may review recently
published rules for ‘‘any questions of
fact, law, and policy the rule may raise.’’
The memorandum notes certain
exceptions that do not apply here. On
January 20, 2021, the Office of
Management and Budget (OMB) also
published OMB Memorandum M–21–
14, Implementation of Memorandum
Concerning Regulatory Freeze Pending
Review, which provides guidance
regarding the Regulatory Freeze
Memorandum. See OMB M–21–14,
Implementation of Memorandum
Concerning Regulatory Freeze Pending
Review, https://www.whitehouse.gov/
wp-content/uploads/2021/01/M-21-14Regulatory-Review.pdf. OMB M–21–14
explains that pursuant to the Regulatory
Freeze Memorandum, agencies ‘‘should
consider postponing the effective dates
for 60 days and reopening the
rulemaking process’’ for ‘‘rules that have
not yet taken effect and about which
questions involving law, fact, or policy
have been raised.’’ Id. In accordance
VerDate Sep<11>2014
17:15 Feb 11, 2021
Jkt 253001
with the Regulatory Freeze
Memorandum and OMB M–21–14, HHS
proposes to delay the effective date of
the final rule revising the Vaccine Injury
Table to April 23, 2021, which would be
60 days beyond its original effective
date. HHS needs to extend the effective
date of the underlying rule by 60 days
to determine whether its promulgation
raises any legal issues, including but not
limited to (1) whether the Advisory
Commission on Childhood Vaccines
was properly notified of the proposed
rule pursuant to 42 U.S.C. 300aa–14(c),
and (2) whether the public was properly
notified of the entire revised regulation,
42 CFR 100.3(b)–(e) (including the
qualifications and aids to interpretation
and the coverage provisions), given that
both the proposed and final rules
published in the Federal Register
included only the revised Vaccine
Injury Table itself, but not the entire
revised regulation. HHS believes that
the proposed delay is reasonable, would
allow HHS time to receive public
comments, and would not be disruptive
since the underlying rule has not yet
taken effect and the agency has not yet
implemented the rule.
HHS seeks comment on the proposed
delay, including the proposed delay’s
impact on any legal, factual, or policy
issues raised by the underlying rule and
whether further review of those issues
warrants such a delay. All other
comments on the underlying rule will
be considered to be outside the scope of
this rulemaking. HHS therefore seeks
comment by February 16, 2021 on its
proposal to extend the effective date by
60 days to April 23, 2021.
Norris Cochran,
Acting Secretary, Department of Health and
Human Services.
[FR Doc. 2021–03069 Filed 2–11–21; 8:45 am]
BILLING CODE 4165–15–P
FEDERAL COMMUNICATIONS
COMMISSION
47 CFR Part 54
[WC Docket No. 21–31; DA 21–98; FRS
17466]
Wireline Competition Bureau Seeks
Comment on Petitions for Emergency
Relief To Allow the Use of E-Rate
Funds To Support Remote Learning
During the COVID–19 Pandemic
Federal Communications
Commission.
ACTION: Solicitation of comments.
AGENCY:
In this document, the
Wireline Competition Bureau (the
SUMMARY:
PO 00000
Frm 00006
Fmt 4702
Sfmt 4702
9309
Bureau) seeks comment on petitions for
emergency relief from parties asking the
Federal Communications Commission
(Commission) to permit the use of ERate program funds to support remote
learning during this unprecedented
public health emergency.
DATES: Comments are due February 16,
2021 and Reply Comments are due
February 23, 2021.
ADDRESSES: Pursuant to sections 1.415
and 1.419 of the Commission’s rules, 47
CFR 1.415, 1.419, interested parties may
file comments on or before February 16,
2021, and reply comments on or before
February 23, 2021. All filings should
refer to WC Docket No. 21–31.
Comments may be filed by paper or by
using the Commission’s Electronic
Comment Filing System (ECFS). See
Electronic Filing of Documents in
Rulemaking Proceedings, 63 FR 24121
(1998).
D Electronic Filers: Comments and
replies may be filed electronically using
the internet by accessing ECFS: https://
www.fcc.gov/ecfs.
D Paper Filers: Parties who choose to
file by paper must file an original and
one copy of each filing. If more than one
docket or rulemaking number appears in
the caption of this proceeding, filers
must submit two additional copies for
each additional docket or rulemaking
number.
D Filings can be sent by commercial
overnight courier or by first-class or
overnight U.S. Postal Service mail.
Filings must be addressed to the
Commission’s Secretary, Office of the
Secretary, Federal Communications
Commission.
D Commercial overnight mail (other
than U.S. Postal Service Express Mail
and Priority Mail) must be sent to 9050
Junction Drive, Annapolis Junction, MD
20701.
D U.S. Postal Service first-class,
Express, and Priority mail must be
addressed to 45 L St NE, Washington,
DC 20554.
Effective March 19, 2020, and until
further notice, the Commission no
longer accepts any hand or messenger
delivered filings. This is a temporary
measure taken to help protect the health
and safety of individuals, and to
mitigate the transmission of COVID–19.
FOR FURTHER INFORMATION CONTACT:
Gabriela Gross, Wireline Competition
Bureau, (202) 418–7400 or by email at
Gabriela.Gross@fcc.gov. We ask that
requests for accommodations be made
as soon as possible in order to allow the
agency to satisfy such requests
whenever possible. Send an email to
fcc504@fcc.gov or call the Consumer
E:\FR\FM\12FEP1.SGM
12FEP1
Agencies
[Federal Register Volume 86, Number 28 (Friday, February 12, 2021)]
[Proposed Rules]
[Pages 9308-9309]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-03069]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
42 CFR Part 100
RIN 0906-AB24
National Vaccine Injury Compensation Program: Revisions to the
Vaccine Injury Table; Notice of Proposed Rulemaking; Public Comment
Period; Delay of Effective Date
AGENCY: Health Resources and Services Administration (HRSA), Department
of Health and Human Services (HHS).
ACTION: Notice of proposed rulemaking; proposed delay of effective
date; request for comments.
-----------------------------------------------------------------------
SUMMARY: In accordance with the Presidential directive as expressed in
the memorandum of January 20, 2021, from the Assistant to the President
and Chief of Staff, entitled ``Regulatory Freeze Pending Review,'' this
action proposes, following a brief public comment period, to further
delay until April 23, 2021, the effective date of the rule entitled
``National Vaccine Injury Compensation Program: Revisions to the
Vaccine Injury Table,'' published in the Federal Register on January
21, 2021. That final rule is scheduled to take effect on February 22,
2021. HHS seeks comments on this proposed delay, which would allow it
additional opportunity for review and consideration of the new rule.
DATES: Written comments and related material to this proposed rule must
be received to the online docket via https://www.regulations.gov on or
before February 16, 2021.
ADDRESSES: You may submit written comments electronically by the
[[Page 9309]]
following method: Federal eRulemaking Portal: https://www.regulations.gov. Follow the instructions on the website for
submitting comments.
Instructions. Include the HHS Docket No. HRSA-2021-0001 in your
comments. All comments received will be posted without change to https://www.regulations.gov. Please do not include any personally identifiable
or confidential business information you do not want publicly
disclosed.
FOR FURTHER INFORMATION CONTACT: Please visit the National Vaccine
Injury Compensation Program's website, https://www.hrsa.gov/vaccinecompensation/, or contact Tamara Overby, Acting Director,
Division of Injury Compensation Programs, Healthcare Systems Bureau,
HRSA, Room 08N146B, 5600 Fishers Lane, Rockville, MD 20857; by email at
[email protected]; or by telephone at (855) 266-2427.
SUPPLEMENTARY INFORMATION: HHS published a notice of proposed
rulemaking on July 20, 2020 (85 FR 43794), and final rule on January
21, 2021 (86 FR 6249). That final rule amended the provisions of 42 CFR
100.3 by removing Shoulder Injury Related to Vaccine Administration,
vasovagal syncope, and Item XVII from the Vaccine Injury Table. The
January 20, 2021, memorandum from the Assistant to the President and
Chief of Staff, entitled ``Regulatory Freeze Pending Review,''
instructed federal agencies to consider delaying the effective date of
rules published in the Federal Register, but which have not yet taken
effect, for a period of 60 days so that the new Administration may
review recently published rules for ``any questions of fact, law, and
policy the rule may raise.'' The memorandum notes certain exceptions
that do not apply here. On January 20, 2021, the Office of Management
and Budget (OMB) also published OMB Memorandum M-21-14, Implementation
of Memorandum Concerning Regulatory Freeze Pending Review, which
provides guidance regarding the Regulatory Freeze Memorandum. See OMB
M-21-14, Implementation of Memorandum Concerning Regulatory Freeze
Pending Review, https://www.whitehouse.gov/wp-content/uploads/2021/01/M-21-14-Regulatory-Review.pdf. OMB M-21-14 explains that pursuant to
the Regulatory Freeze Memorandum, agencies ``should consider postponing
the effective dates for 60 days and reopening the rulemaking process''
for ``rules that have not yet taken effect and about which questions
involving law, fact, or policy have been raised.'' Id. In accordance
with the Regulatory Freeze Memorandum and OMB M-21-14, HHS proposes to
delay the effective date of the final rule revising the Vaccine Injury
Table to April 23, 2021, which would be 60 days beyond its original
effective date. HHS needs to extend the effective date of the
underlying rule by 60 days to determine whether its promulgation raises
any legal issues, including but not limited to (1) whether the Advisory
Commission on Childhood Vaccines was properly notified of the proposed
rule pursuant to 42 U.S.C. 300aa-14(c), and (2) whether the public was
properly notified of the entire revised regulation, 42 CFR 100.3(b)-(e)
(including the qualifications and aids to interpretation and the
coverage provisions), given that both the proposed and final rules
published in the Federal Register included only the revised Vaccine
Injury Table itself, but not the entire revised regulation. HHS
believes that the proposed delay is reasonable, would allow HHS time to
receive public comments, and would not be disruptive since the
underlying rule has not yet taken effect and the agency has not yet
implemented the rule.
HHS seeks comment on the proposed delay, including the proposed
delay's impact on any legal, factual, or policy issues raised by the
underlying rule and whether further review of those issues warrants
such a delay. All other comments on the underlying rule will be
considered to be outside the scope of this rulemaking. HHS therefore
seeks comment by February 16, 2021 on its proposal to extend the
effective date by 60 days to April 23, 2021.
Norris Cochran,
Acting Secretary, Department of Health and Human Services.
[FR Doc. 2021-03069 Filed 2-11-21; 8:45 am]
BILLING CODE 4165-15-P